Clinical benefits of a new piperidine-class AChE inhibitor

European Neuropsychopharmacology

Volumn 9, Issue SUPPL. 2, 1999, Pages

  Doody, Rachelle Smith ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Donepezil; Psychometric testing; Therapy

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL;

ALZHEIMER DISEASE; ARTICLE; COGNITION; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; PSYCHOMETRY; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; HUMANS; INDANS; NOOTROPIC AGENTS; PIPERIDINES; SYNAPTIC TRANSMISSION;

EID: 0032907788     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(98)00047-9     Document Type: Article

References (29)

1. Appleyard M.E. Secreted acetylcholinesterase: Non-classical aspects of a classical enzyme. Trends Neurosci. 15(12):1992;485-490.
2. American Psychiatric Association, 1987. Diagnostic and Statistical Manual of Mental Disorder, 3rd ed. revised, APA, Washington, DC.
3. Berg L., Miller J.P., Baty J., Rubin E.H., Morris J.C., Figiel G. Mild senile dementia of the Alzheimer Type 4. Evaluation of intervention. Ann. Neurol. 31:1992;242-249.
4. Bierer L.M., Haroutunian V., Gabriel S., Knott P.J., Carlin L.S., Purohit D.P., Perl D.P., Schmeidler J., Kanof P., Davis K.L. Neurochemical correlates of dementia severity in Alzheimer's disease: Relative importance of the cholinergic deficits. J. Neurochem. 64(2):1995;749-760.
5. Chatellier G., Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: A multicentre trial. BMJ. 300:1990;495-499.
6. Davis, K.L., Thal, L.J., Gamzu, E.R., Davis, C.S., Woolson, R.F., Gracon, S.I., Drachman, D.A., Schneider, L.S., Whitehouse, P.J., Hoover, T.M., Morris, J.C., Kawas, C.H., Knopman, D.S., Earl, N.L., Kumar, V., Doody, R.S. and The Tacrine Collaborative Study Group, 1992. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease, N. Engl. J. Med. 327, 1253-1259.
7. Farlow M., Gracon S.I., Hershey L.A., Lewis K.W., Sadowsky C.H., Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA. 268(18):1992;2523-2529.
8. Folstein M.F., Folstein S.E., McHugh P.R. 'Mini-Mental State'. A practical method for grading the cognitive state of subjects for the clinician. J. Psychiatr. Res. 12:1975;189-198.
9. Friedhoff, L.T., Rogers, S.L., 1997. Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease - Results of a preliminary evaluation. Neurology 48(3),A100(P02.026).
10. Gauthier S., Bouchard R., Lamontagne A., Bailey P., Bergman H., Ratner J., Tesfaye Y., Saint-Martin M., Bacher Y., Carrier L., Charbonneau R., Clarfield A.M., Collier B., Dastoor D., Gauthier L., Germain M., Kissel C., Kreiger M., Kushnir S., Masson H., Morin J., Nair V., Neirinck L., Suissa S. Tetrahydroaminoacridine-lecithin combination treatment in patient with intermediate-stage Alzheimer's disease. N. Engl. J. Med. 322:1990;1272-1276.
11. Hughes C.P., Berg L., Danziger W.L., Coben L.A., Martin R.L. A new clinical scale for the staging of dementia. Br. J. Psychiatry. 140:1982;566-572.
12. Kawakami Y., Inoue A., Kawai T., Wakita M., Sugimoto H., Hopfinger A.J. The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg. Med. Chem. 4(9):1996;1429-1556.
13. Knapp M.J., Knopman D.S., Solomon P.R., Pendlebury W.W., Davis C.S., Gracon S.I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 271(13):1994;985-991.
14. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944.
15. Mesulam M.M., Geula C., Moran M.A. Anatomy of cholinesterase inhibition in Alzheimer's disease: Effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Ann. Neurol. 22:1987;683-691.
16. Mohs R.C., Davis B.M., Johns C.A., Mathe A.A., Greenwald B.S., Horvath T.B., Davis K.L. Oral physostigmine treatment of patients with Alzheimer's disease. Am. J. Psychiatry. 142:1985;28-33.
17. Nitsch R.M., Slack B.E., Wurtman R.J., Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 258:1992;304-307.
18. Rogers S.L., Friedhoff L.T. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br. J. Clin. Pharmacol. 46(Suppl. 1):1998;1-6.
19. Rogers S.L., Friedhoff L.T. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur. Neuropsychopharmacol. 8:1998;67-75.
20. Rogers, S.L., Yamanishi, Y., Yamatsu, K., 1991. E2020: The pharmacology of a piperidine cholinesterase inhibitor. In: Becker, R., Giacobini, E. (Eds.), Cholinergic Basis for Alzheimer Therapy, Birkhäuser, Boston, pp. 314-320.
21. Rogers, S.L., Friedhoff, L.T., and the Donepezil Study Group, 1996. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial, Dementia 7, 293-303.
22. Rogers, S.L., Doody, R.S., Mohs, R.C., Friedhoff, L.T., and the Donepezil Study Group, 1998a. Donepezil improves cognition and global function in Alzheimer's disease: A 15-week, double-blind, placebo-controlled study, Arch. Int. Med. 158, 1021-1031.
23. Rogers, S.L., Farlow M.R., Doody, R.S., Mohs, R.C., Friedhoff, L.T., and the Donepezil Study Group, 1998b. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease, Neurology 50, 136-145.
24. Rosen W.G., Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. Am. J. Psychiatry. 141(11):1984;1356-1364.
25. Rossor M.N. Neurotransmitters and CNS disease. Lancet. 2:1982;1200-1203.
26. Schneider, L.S., Olin, J.T., Doody, R.S., Clark, C.M., Morris, J.C., Reisberg, B., Schmitt, F.A., Grundman, M., Thomas, R.G., Ferris, S.H. and The Alzheimer's Disease Cooperative Study, 1997. Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical global impression of change, Alzheimer's Disease and Associated Disorders 11 (Suppl. 2), S22-32.
27. Sherman, K.A., 1991. Pharmacodynamics of oral E2020 and tacrine in humans: Novel approaches. In: Becker R., Giacobini, E. (Eds.), Cholinergic Basis for Alzheimer Therapy, Birkhäuser, Boston, pp. 321-328.
28. Thal L.J., Fuld P.A., Masur D.M., Sharpless N.S. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann. Neurol. 13:1983;491-496.
29. TM (donepezil hydrochloride tablets), Eisa: Inc., New Jersey, November 15.